Valuation: Novartis AG

Market Cap 289B 249B 234B 213B 401B 27,631B 406B 2,744B 1,075B 13,843B 1,085B 1,061B 46,049B P/E 2026 *
21.4x
P/E 2027 * 18.3x
Enterprise Value 322B 278B 261B 238B 447B 30,798B 453B 3,058B 1,198B 15,430B 1,209B 1,183B 51,326B EV / Sales 2026 *
5.58x
EV / Sales 2027 * 5.17x
Free-Float
91.66%
Yield 2026 *
2.89%
Yield 2027 * 3.02%
1 day+1.56%
1 week-2.38%
Current month-2.29%
1 month-0.67%
3 months+5.06%
6 months-3.63%
Current year+12.76%
1 week 121.38
Extreme 121.38
128.04
1 month 121.38
Extreme 121.38
131.82
Current year 107.88
Extreme 107.88
131.82
1 year 96.15
Extreme 96.15
131.82
3 years 81.55
Extreme 81.55
131.82
5 years 73.14
Extreme 73.14
131.82
10 years 68.07
Extreme 68.07
131.82
Manager TitleAgeSince
Chief Executive Officer 50 2018-01-31
Director of Finance/CFO - 2026-03-15
Compliance Officer 58 2025-04-13
Director TitleAgeSince
Director/Board Member 67 2014-12-31
Director/Board Member 69 2015-12-31
Director/Board Member 61 2015-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%-2.38% - - 287B
+0.81%-3.21%+70.81%+121.77% 1,052B
+0.52%+0.17%+48.79%+50.71% 627B
+0.31%+0.97%+21.21%+66.90% 441B
+0.28%-4.56%+39.10%+38.05% 349B
+0.78%-2.68%+23.13%+37.32% 287B
+0.87%-3.59%-1.52%+7.12% 241B
+0.16%-0.17%+42.33%+57.85% 224B
-0.78%-4.49%-15.86%-54.13% 202B
+0.18%+4.27%+17.59%+81.36% 172B
Average +0.35%-0.77%+27.29%+45.22% 399.46B
Weighted average by Cap. +0.46%-0.63%+39.97%+64.29%

Financials

2026 *2027 *
Net sales 57.71B 49.82B 46.74B 42.57B 80.04B 5,517B 81.15B 548B 215B 2,764B 217B 212B 9,195B 61.25B 52.88B 49.61B 45.19B 84.96B 5,857B 86.14B 582B 228B 2,934B 230B 225B 9,760B
Net income 13.95B 12.04B 11.3B 10.29B 19.35B 1,334B 19.62B 132B 51.9B 668B 52.38B 51.24B 2,223B 15.5B 13.38B 12.56B 11.44B 21.5B 1,482B 21.8B 147B 57.67B 743B 58.2B 56.94B 2,470B
Net Debt 33.11B 28.59B 26.82B 24.43B 45.93B 3,166B 46.57B 314B 123B 1,586B 124B 122B 5,277B 27.82B 24.01B 22.53B 20.52B 38.58B 2,660B 39.12B 264B 103B 1,333B 104B 102B 4,433B
Logo Novartis AG
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
75,267
Date Price Change Volume
26-08-17 CHF 123.76 +1.56% 130,000
26-08-14 CHF 121.86 -1.69% 130,000
26-08-13 CHF 123.96 -0.29% 130,000
26-08-12 CHF 124.32 -1.63% 130,000
26-08-11 CHF 126.38 -0.32% 130,000
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
22
Last Close Price
150.86USD
Average target price
154.18USD
Spread / Average Target
+2.20%

Quarterly revenue - Rate of surprise